Celcuity (CELC) Common Equity (2016 - 2026)
Celcuity's (CELC) quarterly Common Equity came in at $100.6 million in Q4 2025, down 13.03% YoY from $115.6 million in Q4 2024, and down 14.03% on a QoQ basis from $117.0 million in Q3 2025.
Celcuity (CELC) Common Equity (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of Common Equity data on file, last reported at $100.6 million in Q4 2025.
- Quarterly Common Equity fell 13.03% year-over-year to $100.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $100.6 million (down 13.03% YoY) and the FY2025 annual result came in at $100.6 million, down 13.03% from the prior year.
- Common Equity retreated to $100.6 million in Q4 2025, from $117.0 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $176.7 million in Q2 2024 to a low of $27.0 million in Q2 2021.
- A 5-year average of $94.4 million and a median of $96.7 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2021 — Common Equity jumped 487.16% — and 2025, when it slumped 74.88%.
- Tracing CELC's Common Equity over 5 years: stood at $68.7 million in 2021, then soared by 94.69% to $133.8 million in 2022, then gained by 4.48% to $139.8 million in 2023, then fell by 17.28% to $115.6 million in 2024, then decreased by 13.03% to $100.6 million in 2025.
- The last three Common Equity figures came in at $100.6 million (Q4 2025), $117.0 million (Q3 2025), and $44.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | -12.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.78 Mn |
| Dec 31, 2025 | 100.56 Mn |
| Sep 30, 2025 | 116.96 Mn |
| Jun 30, 2025 | 44.38 Mn |
| Mar 31, 2025 | 86.67 Mn |
| Dec 31, 2024 | 115.62 Mn |
| Sep 30, 2024 | 149.71 Mn |
| Jun 30, 2024 | 176.69 Mn |
| Mar 31, 2024 | 133.74 Mn |
| Dec 31, 2023 | 139.77 Mn |
| Sep 30, 2023 | 92.90 Mn |
| Jun 30, 2023 | 110.13 Mn |
| Mar 31, 2023 | 123.23 Mn |
| Dec 31, 2022 | 133.77 Mn |
| Sep 30, 2022 | 43.53 Mn |
| Jun 30, 2022 | 53.19 Mn |
| Mar 31, 2022 | 61.54 Mn |
| Dec 31, 2021 | 68.71 Mn |
| Sep 30, 2021 | 74.47 Mn |
| Jun 30, 2021 | 27.03 Mn |